Tirzepatide (5mg/10mg/15mg/20mg/30mg)
Brief Introduction:
Tirzepatide is the world's first and currently the only glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Eli Lilly, it was approved for marketing in China on May 21st, 2024, and officially launched on January 2nd, 2025. It is suitable for adult patients with type Ⅱ diabetes whose blood sugar is still poorly controlled by metformin and/or sulfonylurea drugs on the basis of diet control and exercise.
Mechanism of Action:
Tirzepatide integrates the effects of two incretin hormones, GIP and GLP-1, into one molecule, and provides more clinical effects by activating the receptors of these two peptide hormones at the same time. Among them, the activation of GLP-1 receptors delays gastric emptying, reduces appetite, lowers blood sugar and improves insulin sensitivity; while the activation of GIP receptors enhances insulin secretion, reduces glucagon release and promotes fat metabolism.
Clinical Trials & Efficacy:
In a series of clinical trials called SURPASS, Tirzepatide showed excellent efficacy. In the treatment of patients with type Ⅱ diabetes, after monotherapy with Tirzepatide, the average reduction in glycated hemoglobin (HbA1c) in patients reached 2.0% to 2.5%. Among them, the high-dose (15mg) Tirzepatide group was significantly better than the 1mg Semaglutide group (HbA1c reduction of 1.9% vs 2.5%).
Tirzepatide also showed outstanding effects in weight loss. In the SURMOUNT trial (for obese or overweight non-diabetic patients), the average weight loss of patients in the high-dose (15mg) group was 20.9%, with a weight loss of approximately 22.5 kg; the weight loss in the medium-dose (10mg) group was 19.5%, with a weight loss of approximately 20.9 kg. This significant weight loss effect has made Tirzepatide a hot topic in the field of weight loss.
In addition, Tirzepatide may also have more systemic benefits. For example, in terms of fighting heart failure and reducing cardiovascular mortality, Tirzepatide has also shown great advantages and potential. It can reduce insulin resistance and improve myocardial metabolism, also has anti-inflammatory and anti-oxidative stress effects, which can protect the myocardium. The effects of Tirzepatide in promoting weight loss and lowering blood pressure also reduce the burden on the heart.
Video 1:
Video 2:
Weight Loss Mechanism:
The weight loss mechanism of Tirzepatide is mainly related to its activation of GIP and GLP-1 receptors. By activating these receptors, Tirzepatide can reduce appetite, delay gastric emptying and promote fat metabolism, thereby achieving the effect of weight loss. In addition, Tirzepatide can also improve insulin sensitivity and further reduce body weight.
Usage & Dosage:
Tirzepatide is a weekly preparation, usually injected once a week, for the treatment of type Ⅱ diabetes and weight loss. Its dual mechanism makes it an ideal choice for patients with high requirements for blood sugar and weight control.
Specifications of our Tirzepatide (5mg/Vial):
| Test Items | Specifications | |
| Appearance | White or almost white powder | |
| Solubility | Freely soluble in water | |
| Identification by HPLC | The retention time of the principal peak of the test solution corresponds to that of the reference solution, as obtained in the assay | |
| Molecular Ion Mass by MS | 4813.45±1.0 | |
| Amino Acid Content | Asp | 1.6 ~ 2.4 |
| Tyr | 1.6 ~ 2.4 | |
| Lys | 1.6 ~ 2.4 | |
| Ile | 2.0 ~ 3.2 | |
| Leu | 1.6 ~ 2.4 | |
| Val | 0.8 ~ 1.2 | |
| Thr | 1.6 ~ 2.4 | |
| Phe | 1.6 ~ 2.4 | |
| Ser | 4.0 ~ 6.0 | |
| Ala | 3.2 ~ 4.8 | |
| Gly | 3.2 ~ 4.8 | |
| Glu | 3.2 ~ 4.8 | |
| Pro | 3.2 ~ 4.8 | |
| Aib | N/A | |
| AEEA | N/A | |
| Water Content (K. F) | Not more than 8.0% | |
| Solution Clarity and Color | Clear and colorless | |
| Purity (HPLC) | Not less than 99.0% | |
| Related Substances (HPLC) | Total impurities | Not more than 1.0% |
| Maximum single impurity | Not more than 0.5% | |
| Impurities with molecular masses greater than that of Tirzepatide (Size Exclusion) | Not more than 0.50% | |
| Residual Solvents | Acetonitrile | Not more than 410 ppm |
| Methanol | Not more than 3000 ppm | |
| Bacterial Endotoxins | Less than 10 EU/mg | |
| Microbial Limits | TAMC | Not more than 100 CFU/g |
| TYMC | Not more than 100 CFU/g | |
| Trifluoroacetate Ion | Not more than 0.10% | |
| Sodium Ion | Not more than 5.0% | |
| Acetate Ion | Not more than 0.10% | |
| Phosphate Ion | Not more than 0.10% | |
| Peptide Content | Not less than 5.0 mg | |
| Assay (HPLC) | 95.0% ~ 105.0% (On anhydrous and salt-free substance basis) | |
Specifications of our Tirzepatide (15mg/Vial):
| Test Items | Specifications | |
| Appearance | White or almost white powder | |
| Solubility | Freely soluble in water | |
| Identification by HPLC | The retention time of the principal peak of the test solution corresponds to that of the reference solution, as obtained in the assay | |
| Molecular Ion Mass by MS | 4813.45±1.0 | |
| Amino Acid Content | Asp | 1.6 ~ 2.4 |
| Tyr | 1.6 ~ 2.4 | |
| Lys | 1.6 ~ 2.4 | |
| Ile | 2.0 ~ 3.2 | |
| Leu | 1.6 ~ 2.4 | |
| Val | 0.8 ~ 1.2 | |
| Thr | 1.6 ~ 2.4 | |
| Phe | 1.6 ~ 2.4 | |
| Ser | 4.0 ~ 6.0 | |
| Ala | 3.2 ~ 4.8 | |
| Gly | 3.2 ~ 4.8 | |
| Glu | 3.2 ~ 4.8 | |
| Pro | 3.2 ~ 4.8 | |
| Aib | N/A | |
| AEEA | N/A | |
| Water Content (K. F) | Not more than 8.0% | |
| Solution Clarity and Color | Clear and colorless | |
| Purity (HPLC) | Not less than 99.0% | |
| Related Substances (HPLC) | Total impurities | Not more than 1.0% |
| Maximum single impurity | Not more than 0.5% | |
| Impurities with molecular masses greater than that of Tirzepatide (Size Exclusion) | Not more than 0.50% | |
| Residual Solvents | Acetonitrile | Not more than 410 ppm |
| Methanol | Not more than 3000 ppm | |
| Bacterial Endotoxins | Less than 10 EU/mg | |
| Microbial Limits | TAMC | Not more than 100 CFU/g |
| TYMC | Not more than 100 CFU/g | |
| Trifluoroacetate Ion | Not more than 0.10% | |
| Sodium Ion | Not more than 5.0% | |
| Acetate Ion | Not more than 0.10% | |
| Phosphate Ion | Not more than 0.10% | |
| Peptide Content | Not less than 15.0 mg | |
| Assay (HPLC) | 95.0% ~ 105.0% (On anhydrous and salt-free substance basis) | |
Specifications of our Tirzepatide (60mg/Vial):
| Test Items | Specifications | |
| Appearance | White or almost white powder | |
| Solubility | Freely soluble in water | |
| Identification by HPLC | The retention time of the principal peak of the test solution corresponds to that of the reference solution, as obtained in the assay | |
| Molecular Ion Mass by MS | 4813.45±1.0 | |
| Amino Acid Content | Asp | 1.6 ~ 2.4 |
| Tyr | 1.6 ~ 2.4 | |
| Lys | 1.6 ~ 2.4 | |
| Ile | 2.0 ~ 3.2 | |
| Leu | 1.6 ~ 2.4 | |
| Val | 0.8 ~ 1.2 | |
| Thr | 1.6 ~ 2.4 | |
| Phe | 1.6 ~ 2.4 | |
| Ser | 4.0 ~ 6.0 | |
| Ala | 3.2 ~ 4.8 | |
| Gly | 3.2 ~ 4.8 | |
| Glu | 3.2 ~ 4.8 | |
| Pro | 3.2 ~ 4.8 | |
| Aib | N/A | |
| AEEA | N/A | |
| Water Content (K. F) | Not more than 8.0% | |
| Solution Clarity and Color | Clear and colorless | |
| Purity (HPLC) | Not less than 99.0% | |
| Related Substances (HPLC) | Total impurities | Not more than 1.0% |
| Maximum single impurity | Not more than 0.5% | |
| Impurities with molecular masses greater than that of Tirzepatide (Size Exclusion) | Not more than 0.50% | |
| Residual Solvents | Acetonitrile | Not more than 410 ppm |
| Methanol | Not more than 3000 ppm | |
| Bacterial Endotoxins | Less than 10 EU/mg | |
| Microbial Limits | TAMC | Not more than 100 CFU/g |
| TYMC | Not more than 100 CFU/g | |
| Trifluoroacetate Ion | Not more than 0.10% | |
| Sodium Ion | Not more than 5.0% | |
| Acetate Ion | Not more than 0.10% | |
| Phosphate Ion | Not more than 0.10% | |
| Peptide Content | Not less than 60.0 mg | |
| Assay (HPLC) | 95.0% ~ 105.0% (On anhydrous and salt-free substance basis) | |
Laboratory & Equipment Display:
Modes of Transport:
Payment Methods:
Storage Conditions:
Preserved in air tight containers, protected from light.
(Recommended temperature: -25℃ ~ -15℃)
Shelf Life:
24 months from the date of manufacturing when stored under the above conditions.
